肺炎治療市場：肺炎タイプ、治療タイプ、流通チャネル、地域別、2026～2032年

肺炎治療市場の評価-2026～2032年

肺炎の流行が拡大していることから、抗生物質、ワクチン、支持療法などの効果的な治療オプションの必要性が高まっています。世界保健機関（WHO）は、肺炎は依然として5歳以下の小児の死因の第1位であり、治療法の進歩が不可欠であることを強調し、2024年には26億9,000万米ドル、2032年には46億8,000万米ドルに達すると発表しています。

さらに、肺炎の原因菌である抗生物質耐性株の出現により、製薬会社はより効果的な新しい治療法の研究開発に投資しています。世界中の政府や保健機関は、肺炎の予防と治療にますます注力しており、これが肺炎治療薬市場の拡大を後押ししています。この市場成長は、2026年から2032年にかけて年平均成長率（CAGR）約7.18%で拡大すると予想されています。

肺炎治療市場定義/概要

肺炎治療とは、肺炎を治療・治癒するために使用される治療法や介入策を指し、肺炎は片方または両方の肺の気嚢に炎症を引き起こす感染症です。抗生物質、抗ウイルス薬、抗真菌薬、ワクチン、酸素療法などの支持療法が治療の一例です。肺炎治療の主要用途は、小児、高齢者、免疫力の低下した患者など、さまざまな患者集団における細菌性、ウイルス性、真菌性の肺炎の治療です。肺炎治療の将来は有望であり、より効果的な薬剤の開発、抗生物質耐性との闘い、ワクチンなどの予防手段の改善を目指した研究が進められています。感染症に対する意識の高まりと政府の取り組みにより、肺炎治療市場は今後数年で飛躍的に拡大すると予想されます。

より効果的な新治療法の研究開発が肺炎治療市場を牽引？

より効果的な新治療法の研究開発が重視されるようになったことは、肺炎治療市場の主要な促進要因です。製薬会社や研究機関は、特に抗生物質耐性の増加を考慮して、肺炎と闘うための新しい抗生物質、抗ウイルス薬、ワクチンの開発への投資を増やしています。例えば、2023年6月、Pfizer社は、多くの肺炎の原因菌である肺炎球菌を標的とした新しいワクチンの第III相検査で有望な結果が得られたと報告しました。このワクチンは、現在の選択肢よりも広範な防御を提供することを目的としており、肺炎の予防と治療における大きな進歩を意味します。

肺炎研究に対する政府の支援と資金は、この動向に貢献しています。2023年8月、米国国立衛生ラボ（NIH）は、次世代抗生物質と代替肺炎治療法の開発を目的としたプロジェクトに追加資金を提供しました。このような政府支援の増加は、特に小児や高齢者といった社会的弱者における肺炎対策の重要性を強調しています。民間部門と公的部門の両方が資金提供する現在進行中の研究開発努力は、この深刻な呼吸器疾患と闘うための新しい治療法の入手可能性と有効性が高まるにつれて、肺炎治療市場の大幅な成長を促進すると予想されます。

抗生物質耐性問題の拡大は肺炎治療市場の成長を阻害するか？

抗生物質耐性問題の拡大は、肺炎治療市場の成長を大きく阻害すると予想されます。細菌病原体が既存の抗生物質に対して耐性を持つようになると、現在の治療法の有効性が低下し、その結果、肺炎の症例がより複雑化・重症化します。このような耐性菌の動向により、新しい抗生物質や治療戦略の開発が必要となり、研究開発への多額の投資が必要となります。さらに、効果のない治療は、ヘルスケアシステムに高いコストと入院期間の長期化をもたらし、リソースにさらなる負担をかけ、市場の成長を阻害します。

さらに、抗生物質耐性の増加は、より個別化された標的治療を必要とし、治療プロトコルを複雑にし、新しい治療の導入を遅らせています。耐性感染症の管理が複雑化することで、ヘルスケアプロバイダはそのアプローチを適応させる必要に迫られ、市場拡大にとって厳しい環境が生まれます。耐性パターンが変化し、新たな菌株が出現するにつれて、肺炎の治療環境はより複雑になり、市場成長への新たな課題となっています。

目次

第1章 イントロダクション

• 市場の定義
• 市場セグメンテーション
• 調査手法

第2章 エグゼクティブサマリー

• 主要調査結果
• 市場概要
• 市場ハイライト

第3章 市場概要

• 市場規模と成長の可能性
• 市場動向
• 市場促進要因
• 市場抑制要因
• 市場機会
• ポーターのファイブフォース分析

第4章 肺炎治療市場：肺炎タイプ別

• 市中肺炎（CAP）
• 院内肺炎（HAP）
• 人工呼吸器関連肺炎（VAP）

第5章 肺炎治療市場：治療タイプ別

• 抗生物質
• 抗ウイルス薬
• 抗真菌薬
• 支持療法
• ワクチン

第6章 肺炎治療市場：流通チャネル別

• 病院薬局
• 小売薬局
• オンライン薬局

第7章 地域別分析

• 北米
• 米国
• カナダ
• メキシコ
• 欧州
• 英国
• ドイツ
• フランス
• イタリア
• アジア太平洋
• 中国
• 日本
• インド
• オーストラリア
• ラテンアメリカ
• ブラジル
• アルゼンチン
• チリ
• 中東・アフリカ
• 南アフリカ
• サウジアラビア
• アラブ首長国連邦

第8章 市場力学

• 市場促進要因
• 市場抑制要因
• 市場機会
• COVID-19の市場への影響

第9章 競合情勢

• 主要企業
• 市場シェア分析

第10章 企業プロファイル

• AstraZeneca
• F. Hoffmann-La Roche Ltd.
• Mylan N.V.
• Teva Pharmaceutical Industries Ltd.
• Sanofi
• Novartis AG
• Pfizer Inc.
• GlaxoSmithKline plc.
• Abbott Laboratories

第11章 市場展望と機会

• 新興技術
• 今後の市場動向
• 投資機会

第12章 付録

• 略語リスト
• 供給源と参考文献

Pneumonia Therapeutics Market Valuation - 2026-2032

This growing prevalence has increased the need for effective treatment options such as antibiotics, vaccines, and supportive care. The World Health Organization (WHO) has stated that pneumonia is still the leading cause of death in children under the age of five, emphasizing the critical need for therapeutic advancements is fueling USD 2.69 Billion in 2024 and reaching USD 4.68 Billion by 2032.

Furthermore, the emergence of antibiotic-resistant strains of pneumonia-causing bacteria has prompted pharmaceutical companies to invest in R&D for new and more effective treatments. Governments and health organizations around the world are focusing more on pneumonia prevention and treatment, which is helping to expand the pneumonia therapeutics market fuels market growth is expected to grow at a CAGR of about 7.18% from 2026 to 2032.

Pneumonia Therapeutics Market: Definition/ Overview

Pneumonia therapeutics refers to the medical treatments and interventions used to treat and cure pneumonia, which is an infection that causes inflammation of the air sacs in one or both lungs. Antibiotics, antivirals, antifungals, vaccines, and supportive care like oxygen therapy are examples of therapeutics. The primary use of pneumonia therapeutics is to treat bacterial, viral, and fungal pneumonia in a variety of patient populations, including children, the elderly, and those with weakened immune systems. The future of pneumonia therapeutics looks promising, with ongoing research aimed at developing more effective drugs, combating antibiotic resistance, and improving preventive measures such as vaccines. With rising awareness and government initiatives to combat infectious diseases, the market for pneumonia therapeutics is expected to expand dramatically in the coming years.

Will Rising Research and Developments of New and More Effective Treatments Drive the Pneumonia Therapeutics Market?

The increasing emphasis on research and development of new and more effective treatments is a major driver of the pneumonia therapeutics market. Pharmaceutical companies and research institutions are increasing their investments in the development of new antibiotics, antivirals, and vaccines to combat pneumonia, particularly in light of rising antibiotic resistance. For instance, in June 2023, Pfizer reported promising results from Phase III trials of a new vaccine targeting Streptococcus pneumoniae, the bacteria that causes many pneumonia cases. This vaccine, which aims to provide broader protection than current options, represents a significant advance in pneumonia prevention and treatment.

Government support and funding for pneumonia research contribute to this trend. In August 2023, The National Institutes of Health (NIH) of the United States provided additional funding for projects aimed at developing next-generation antibiotics and alternative pneumonia therapies. This increase in government support emphasizes the importance of combating pneumonia, particularly among vulnerable populations such as children and the elderly. The ongoing research and development efforts, funded by both the private and public sectors, are expected to drive significant growth in the pneumonia therapeutics market as new treatments become more available and effective in combating this serious respiratory condition.

Will Growing Issues of Antibiotic Resistance Hinder the Growth of the Pneumonia Therapeutics Market?

The growing issue of antibiotic resistance is expected to significantly impede the growth of the pneumonia therapeutics market. As bacterial pathogens become more resistant to existing antibiotics, the effectiveness of current treatments declines, resulting in more complicated and severe cases of pneumonia. This resistance trend necessitates the development of new antibiotics and therapeutic strategies, which requires significant investment in R&D. Furthermore, ineffective treatments cause healthcare systems to incur higher costs and longer hospital stays, putting additional strain on resources and impeding market growth.

Furthermore, the rise in antibiotic resistance necessitates more personalized and targeted therapies, complicating treatment protocols and delaying the introduction of new therapeutics. The increased complexity of managing resistant infections places additional pressure on healthcare providers to adapt their approaches, creating a challenging environment for market expansion. As resistance patterns shift and new strains emerge, the therapeutic landscape for pneumonia becomes more complex, posing new challenges to market growth.

Category-Wise Acumens

Will Rising Cases of Community-Acquired Pneumonia Propel the Pneumonia Therapeutics Market?

Rising cases of Community-Acquired Pneumonia (CAP) are expected to boost the pneumonia therapeutics market, enabling the segment hold major in the market. CAP is still one of the most common types of pneumonia, affecting a sizable proportion of the global population, particularly the elderly and those with chronic conditions. This increased prevalence creates a need for effective treatments and preventive measures.

Furthermore, government initiatives to improve public health responses to pneumonia are helping to drive market growth. In July 2024, the World Health Organization (WHO) launched a new initiative to improve pneumonia care in low-resource settings, including increasing access to effective treatments and vaccines. These actions are expected to increase demand for pneumonia therapeutics, resulting in further market growth as healthcare systems around the world work to manage and reduce the burden of CAP.

The market's fastest-growing segment is ventilator-associated pneumonia (VAP). This expansion is primarily driven by the increased use of mechanical ventilation in critically ill patients, as well as the growing recognition of VAP as a significant healthcare concern. The emphasis on improving outcomes for ventilator-dependent patients, combined with advances in technology and infection control practices, is driving the expansion of therapeutic options for VAP. As healthcare facilities work to reduce VAP incidence and improve patient care, the need for targeted treatments and preventative measures grows.

Will Rising Sales through Hospital Pharmacies Fuel the Pneumonia Therapeutics Market?

The hospital pharmacies are expected to dominate the pneumonia therapeutics market. Hospital pharmacies play an important role in providing specialized and immediate treatment options for pneumonia patients, including advanced therapies that may not be available through retail or online channels. This trend is supported by recent developments; for instance, in September 2024, GlaxoSmithKline (GSK) expanded its partnership with major hospital networks to distribute its latest pneumonia vaccine, emphasizing the critical role of hospital pharmacies in reaching patients with severe cases or those requiring specialized care. This move emphasizes the growing role of hospital pharmacies in the therapeutic landscape.

Furthermore, rising incidences and complications are expected to drive up demand for pneumonia therapeutics in these settings. In August 2024, the United States Centers for Disease Control and Prevention (CDC) reported an increase in hospitalizations due to severe pneumonia cases, prompting healthcare systems to improve their therapeutic protocols. This surge translates into increased sales through hospital pharmacies, which are primary points of care for patients requiring immediate and comprehensive treatment, driving market growth.

Online pharmacies are the fastest growing segment of the market. This growth is being driven by the increased adoption of digital health solutions as well as the convenience of online shopping. Patients and healthcare providers are increasingly using online platforms to access medications due to their convenience, competitive pricing, and ease of prescription refilling. The expansion of e-commerce and advances in telemedicine are expected to accelerate the growth of online pharmacies in the pneumonia therapeutics market.

Country/Region-wise

Will High Prevalence of Pneumonia in North America Drive the Pneumonia Therapeutics Market?

The high incidence of pneumonia in North America is projected to lead to the dominance of this region in pneumonia therapeutics market. The region has a significant number of pneumonia cases, particularly among the elderly and immunocompromised people. In response, there is a growing need for effective therapeutic solutions. For instance, In June 2023, the US Centers for Disease Control and Prevention (CDC) reported that pneumonia is still one of the leading causes of hospitalization among older adults in the United States. This ongoing health challenge has prompted investments in advanced pneumonia treatments and vaccines, resulting in market growth.

Furthermore, pharmaceutical companies in North America are actively involved in improving pneumonia treatments through innovation and collaboration. In July 2023, Merck & Co. announced that it would expand its pneumonia vaccine portfolio with the launch of a new vaccine targeting multiple strains of Streptococcus pneumoniae, the bacteria that causes many pneumonia cases. The United States government's support for research and development in this area, including grants and clinical trial funding, boosts the market even more. These factors are expected to continue propelling the pneumonia therapeutics market in North America, making it one of the most dynamic regions on the global stage.

Will Increasing Government Initiatives to Combat Infectious Diseases in Asia-Pacific Propel the Pneumonia Therapeutics Market?

Increasing government initiatives to combat infectious diseases in Asia-Pacific is projected to help the region witness rapid growth in the pneumonia therapeutics market. The region's governments are implementing extensive vaccination programs and awareness campaigns to reduce the incidence of pneumonia, particularly among vulnerable populations such as children and the elderly. For instance, in August 2023, the Indian government launched an expanded immunization drive that included the pneumococcal conjugate vaccine (PCV) as part of its Universal Immunization Programme, with the goal of lowering pneumonia-related child mortality. These initiatives are increasing demand for pneumonia vaccines and therapeutics, resulting in market growth.

Furthermore, collaborations between governments and pharmaceutical companies help to expand the market. In July 2023, Pfizer announced a collaboration with the Chinese government to improve access to pneumonia vaccines in rural areas, as part of China's Healthy China 2030 initiative. Such collaborations are expanding the availability of pneumonia treatments and improving healthcare infrastructure in Asia-Pacific, positioning the region as a key growth driver for the global pneumonia therapeutics market. These combined efforts are expected to maintain the market's momentum in the coming years.

Competitive Landscape

The competitive landscape of the pneumonia therapeutics market is shaped by a diverse range of pharmaceutical companies, biotech firms, and research institutions that are focusing on developing innovative treatments. These include emerging players working on novel antibiotics, antiviral drugs, and biologics aimed at addressing antibiotic-resistant strains of pneumonia. Collaborations between smaller biotech companies and larger pharmaceutical firms are common, facilitating the development and commercialization of new therapies. Additionally, government initiatives and funding for research into more effective pneumonia treatments contribute to the competitive dynamics of the market.

Some of the prominent players operating in the pneumonia therapeutics market include:

• AstraZeneca
• Hoffmann-La Roche Ltd.
• Mylan N.V.
• Teva Pharmaceutical Industries Ltd.
• Sanofi
• Pfizer, Inc.
• GlaxoSmithKline plc.
• Abbott Laboratories

Latest Developments

• In June 2024, GSK announced positive results from a phase III clinical trial for a novel antibiotic designed to treat multidrug-resistant pneumonia. The drug, intended to combat hospital-acquired bacterial infections, demonstrated significant efficacy, indicating a potential breakthrough in pneumonia treatment.
• In February 2024, Novartis completed the acquisition of a start-up focused on developing novel treatments for pneumonia, particularly in patients with chronic respiratory illnesses. This acquisition is part of Novartis' overall strategy to strengthen its respiratory disease portfolio.
• Johnson & Johnson announced a collaboration with an artificial intelligence company in January 2024 to accelerate the discovery of new antibiotics for pneumonia. The collaboration intends to use AI to identify novel drug candidates that can overcome current treatment limitations.

Pneumonia Therapeutics Market, By Category

• Type of Pneumonia:
• Community-Acquired Pneumonia (CAP)
• Hospital-Acquired Pneumonia (HAP)
• Ventilator-Associated Pneumonia (VAP)
• Treatment Type:
• Antibiotics
• Antiviral Drugs
• Antifungal Drugs
• Supportive Therapies
• Vaccines
• Distribution Channel:
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Region:
• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East & Africa

TABLE OF CONTENTS

1. Introduction

• Market Definition
• Market Segmentation
• Research Methodology

2. Executive Summary

• Key Findings
• Market Overview
• Market Highlights

3. Market Overview

• Market Size and Growth Potential
• Market Trends
• Market Drivers
• Market Restraints
• Market Opportunities
• Porter's Five Forces Analysis

4. Pneumonia Therapeutics Market, By Type of Pneumonia

• Community-Acquired Pneumonia (CAP)
• Hospital-Acquired Pneumonia (HAP)
• Ventilator-Associated Pneumonia (VAP)

5 Pneumonia Therapeutics Market, By Treatment Type

• Antibiotics
• Antiviral Drugs
• Antifungal Drugs
• Supportive Therapies
• Vaccines

6 Pneumonia Therapeutics Market, By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

7. Regional Analysis

• North America
• United States
• Canada
• Mexico
• Europe
• United Kingdom
• Germany
• France
• Italy
• Asia-Pacific
• China
• Japan
• India
• Australia
• Latin America
• Brazil
• Argentina
• Chile
• Middle East and Africa
• South Africa
• Saudi Arabia
• UAE

8. Market Dynamics

• Market Drivers
• Market Restraints
• Market Opportunities
• Impact of COVID-19 on the Market

9. Competitive Landscape

• Key Players
• Market Share Analysis

10. Company Profiles

• AstraZeneca
• F. Hoffmann-La Roche Ltd.
• Mylan N.V.
• Teva Pharmaceutical Industries Ltd.
• Sanofi
• Novartis AG
• Pfizer Inc.
• GlaxoSmithKline plc.
• Abbott Laboratories

11. Market Outlook and Opportunities

• Emerging Technologies
• Future Market Trends
• Investment Opportunities

12. Appendix

• List of Abbreviations
• Sources and References